TAMAR MERMELSTEIN: Open Payments
NPI 1811411267 · RIDGEWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$935 in 65 payments from 16 companies in 2025. Trend: 2023 $875 · 2024 $1,175 · 2025 $935
Food & beverage: $935
| Company | Payments | Amount |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | 20 | $184 |
| Novartis Pharmaceuticals Corporation | 5 | $111 |
| Incyte Corporation | 6 | $94 |
| Regeneron Healthcare Solutions, Inc. | 4 | $70 |
| PFIZER INC. | 4 | $66 |
| Botanix SB Inc | 3 | $57 |
| Galderma Laboratories, L.P. | 3 | $54 |
| Arcutis Biotherapeutics, Inc. | 3 | $52 |
| Organon LLC | 4 | $51 |
| Janssen Biotech, Inc. | 3 | $43 |
Products named: ILUMYA, OPZELURA, CIBINQO, COSENTYX, SOFDRA, NEMLUVIO, Zoryve, VTAMA.
Industry payments across NJ — which companies pay providers there.
